Intervention not reported
Proportion of participants with 1 or more serious adverse events at maximum · adults with compensated or decompensated advanced chronic liver disease
It is very uncertain whether the intervention changes proportion of participants with 1 or more serious adverse events at… (very low certainty).
1 finding from 1 review
Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke
1 finding from 1 review
Adverse events or toxicity: differences in rates of specific adverse events · adults and children with sickle cell disease and an increased risk of stroke
1 finding from 1 review
Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Felbamate plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis
Corticosteroids leads to higher number of participants with adverse events ‐ muscle weakness (up to… compared with placebo or usual care (high certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Serious adverse events (≥ 1 symptom related to study drug or not) (Range of · infants
IPV‐OPV showed no clear difference in serious adverse events (≥ 1 symptom related to study drug or not)… compared with IPV (low certainty).
1 finding from 1 review
Falls · people with stroke
It is very uncertain whether circuit class therapy changes adverse events (falls) from all available trials Counts of numbers… compared with other intervention (very low certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (nosocomial infection) (penicillin versus cefotaxime) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes serious adverse events (nosocomial infection) (penicillin versus… compared with other antibiotics (very low certainty).
1 finding from 1 review
Adverse events: Oral cavity disorders (includes oral dryness and mucositis)‐ · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Oral cavity disorders (includes oral dryness and… compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events Respiratory infection (pneumonia) Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in adverse events Respiratory infection (pneumonia) Nasal mucosa or… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review